PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用  

PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Ls antibodies in cancer therapy

作　　者：潘佳佳[1] 贾晓青[1] 黄岗[1] 张玉彬[1] 

机构地区：[1]中国药科大学生命科学与技术学院,南京210009

出　　处：《中国药科大学学报》2016年第1期9-18,共10页Journal of China Pharmaceutical University

摘　　要：程序性死亡受体-1(PD-1)是T细胞上主要存在的一种抑制性受体,与其配体PD-L1、PD-L2相互作用,可抑制T细胞增殖、活化和细胞因子的分泌。在正常机体中,PD-1/PD-Ls信号通路对维持机体的免疫耐受具有重要作用;而在肿瘤发生时,PD-1/PD-Ls信号通路能抑制T细胞的免疫反应而促进肿瘤免疫逃逸的发生。本文从PD-1/PD-Ls的结构与表达、信号通路的作用机制、PD-1/PD-L1的可溶性分子(s PD-1/s PD-L1)的表达特性及其对PD-1/PD-Ls途径的作用等方面简述了PD-1/PD-Ls信号通路的研究现状,综述了抗PD-1/PD-Ls抗体及其在肿瘤免疫治疗中的临床应用。Programmed death-l（PD-1） is a major co-suppression receptor expressed oll T cells. Binding with its ligands （PD-L1 anti PD-L2）, PD-1 can inhibit T cell proliferation, activation and cytokine secretion. In normal organs, PD-1/PD-Ls signaling pathway plays an important role in maintaining immune tolerance, while suppress- ing T cell immune response and promoting tumor immune escape during tumorigenesis. This article reviews the research progress on PD-1/PD-Ls signaling pathway from the structure and expression of PD-1/PD-Ls, the mech- anism of the signaling pathway as well as the expression characteristics of soluble form of PD-1/PD-LI （sPD-1/ sPD-LI）, and summarizes the categories of anti-PD-1/PD-Ls antibodies and their clinical trials in cancer immu- notherapy.

关 键 词：程序性死亡受体-1 程序性死亡受体配体1 单克隆抗体 抗肿瘤 进展 

分 类 号：R730.5[医药卫生—肿瘤]